INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results